Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera's mAbs target S100 proteins implicated in driving cancer metastases
BioCentury | Mar 29, 2017
Distillery Techniques

Biomarkers

BioCentury | Feb 16, 2015
Clinical News

APPY1 regulatory update

BioCentury | Jan 19, 2015
Clinical News

APPY1 regulatory update

BioCentury | Jul 28, 2014
Clinical News

APPY1 regulatory update

BioCentury | Jun 26, 2014
Distillery Therapeutics

Indication: Cancer

BioCentury | May 29, 2014
Targets & Mechanisms

S100A9-clot not, bleed not

BioCentury | Apr 7, 2014
Clinical News

APPY1 regulatory update

BioCentury | Mar 17, 2014
Clinical News

APPY1: Pivotal trial data

Items per page:
1 - 10 of 23